Current Use of Non-steroidal Anti-inflammatory Drugs in the Treatment of Ocular Inflammation Related to Cataract Surgery

2012 ◽  
Vol 06 (03) ◽  
pp. 173 ◽  
Author(s):  
Eric Donnenfeld ◽  
Keyword(s):  
Cataract Surgery ◽  
Ocular Inflammation ◽  
Cystoid Macular Oedema ◽  
Effective Management ◽  
Ocular Pain ◽  
Reduction Of Pain ◽  
Inflammatory Drugs ◽  
Anti Inflammatory ◽  
Systemic Responses ◽  
Topical Nsaids

Ocular inflammation and pain are a common consequence of cataract surgery, and if left untreated, may lead to extensive ocular damage, resulting in impaired vision as well as decreased satisfaction with the procedure. Effective management of ophthalmic inflammation after surgery is therefore vital. Topical ophthalmic non-steroidal anti-inflammatory drugs (NSAIDs) have become a mainstay of management of ocular pain and inflammation as a result of their anti-inflammatory activity, analgesic property and established safety record. Numerous studies have demonstrated the efficacy of topical NSAIDs in post-operative prevention of ocular inflammation, inhibition of intra-operative miosis, reduction of pain associated with cataract surgery and pre-operative use to prevent cystoid macular oedema. Studies have also indicated that NSAIDs and steroids act synergistically when administered together, and that a combination of steroid and NSAID therapy is recommended to achieve successful outcomes. With appropriate administration, NSAIDs are safe and effective therapeutic agents, which rarely result in serious local and systemic responses.

Redefining the Treatment Paradigm for Post-operative Inflammation Control – The Role of Topical Non-steroidal Anti-inflammatory Drugs

2010 ◽  
Vol 04 (01) ◽  
pp. 54 ◽  
Author(s):  
Oliver Findl ◽  
Keyword(s):  
Current Treatment ◽  
Ocular Inflammation ◽  
Cystoid Macular Oedema ◽  
European Medicines Agency ◽  
Pharmacological Properties ◽  
New Agents ◽  
Treatment Paradigm ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Topical ophthalmic non-steroidal anti-inflammatory drugs (NSAIDs) are used in the treatment of post-operative ocular inflammation and pain following cataract surgery and for some other clinical applications of ophthalmology, including cystoid macular oedema. Products vary by their pharmacological properties, clinical efficacy and tolerability, which affect their place in therapy for new agents in Europe. The pharmacological properties of topical ophthalmic NSAIDs and their place in current treatment of post-operative ocular inflammation are discussed in this article, focussing on bromfenac, which has been submitted for approval by the European Medicines Agency (EMEA).

Bilateral fingolimod-associated macular oedema development after cataract surgery

2021 ◽  
Vol 14 (6) ◽  
pp. e240562
Author(s):  
Matthew Gillam ◽  
Theresa Richardson
Keyword(s):  
Multiple Sclerosis ◽  
Cataract Surgery ◽  
Macular Oedema ◽  
Topical Therapy ◽  
Cystoid Macular Oedema ◽  
Topical Steroids ◽  
Visual Recovery ◽  
Anti Inflammatory

Postoperative cystoid macular oedema (CMO) is a recognised complication of cataract surgery, occurring in around 1.5% of cases. It is generally managed with topical steroids or non-steroidal anti-inflammatory medications. We present a case of a patient who developed bilateral sequential CMO following bilateral sequential cataract surgery which was non-responsive to topical therapy and worsened following sub-Tenons administration of steroid. The patient took fingolimod for multiple sclerosis both prior to and during the period of cataract surgery which is known to result in the development of macular oedema in some patients. On fingolimod cessation, the oedema resolved over a period of 5 months with good visual recovery. We present this case to inform cataract surgeons of the risk of fingolimod-associated macular oedema in patients undergoing cataract surgery and to inform neurologists of the potential need to adjust treatment for patients undergoing cataract surgery.

Topical Nonsteroidal Anti-Inflammatory Drugs in Uncomplicated Cataract Surgery: Effect of Sodium Naproxen

2005 ◽  
Vol 15 (5) ◽  
pp. 598-606 ◽  
Author(s):  
P. Russo ◽  
V. Papa ◽  
S. Russo ◽  
A. Dl Bella ◽  
G. Pabst ◽  
...  
Keyword(s):  
Cataract Surgery ◽  
Ophthalmic Solution ◽  
Controlled Study ◽  
Topical Formulation ◽  
Serious Adverse Events ◽  
Suitable Alternative ◽  
Postoperative Inflammation ◽  
Sodium Naproxen ◽  
Inflammatory Drugs ◽  
Anti Inflammatory

Purpose To investigate whether topical nonsteroidal anti inflammatory drugs (NSAIDs) are useful, in the absence of concomitant corticosteroid therapy, in limiting postoperative inflammation after uncomplicated cataract surgery. Methods A total of 328 patients were enrolled in a prospective, randomized, double-masked, parallel-group, active-controlled study. Anterior chamber inflammation (ACI) was evaluated as the primary efficacy parameter. Only patients with moderate inflammation (ACI score of ≤4) the day after surgery were randomized and treated with NSAIDs. A novel topical formulation containing 0.2% sodium naproxen was compared with 0.1% diclofenac. Both were administered three times a day for 14 consecutive days. Ocular inflammation was measured after 7 and 14 days by using slit-lamp biomicroscopy. Safety parameters were also evaluated at the same time. Results Both treatments were equally effective in controlling postsurgical inflammation. No statistically significant differences between treatment groups were observed for the safety variables. No serious adverse events (AEs) occurred during the course of the study. The most frequent AE reported with naproxen was eye redness. Conclusions NSAIDs can effectively be used without concurrent administration of corticosteroids to control postoperative inflammation after uncomplicated cataract surgery. In addition, naproxen ophthalmic solution may be considered a suitable alternative to the currently available NSAIDs.

Sign in / Sign up

Export Citation Format

Share Document